about
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's diseaseTolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.Review: management of Parkinson's disease.The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in miceCurrent status of symptomatic medical therapy in Parkinson's diseaseTreatment of levodopa-induced motor complications.Pharmacologic safety concerns in Parkinson's disease: facts and insights.Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Cutaneous Adverse Effects of Neurologic Medications.Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.Measuring interference of drug-like molecules with the respiratory chain: toward the early identification of mitochondrial uncouplers in lead finding.Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT).Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.The liver toxicity biomarker study: phase I design and preliminary results.Low-coordinate cobalt(II) terphenyl complexes: precursors to sterically encumbered ketones.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q24657680-47BB0250-69F2-48F0-863E-FEEEFBED2D7CQ33775239-BA38136C-80D1-43DC-B054-978395A5491CQ34332812-8B556717-767E-47F2-9CE0-966B6EFEB890Q35871663-E68932E2-23DC-4BA6-90BA-7F0E6C58F08AQ37131229-460EDFDE-8992-49FE-BD6D-9F7E6F20021DQ37264482-65F45F2F-AA02-4A35-97BB-A80C85B3BF4AQ37950427-E8701B26-A8CB-4CCE-8D60-B6BF8D129914Q37954392-12140088-5682-4E12-BAC3-EDDFA2566D60Q38223072-1A7D8513-87A0-47E8-8BC8-A5BF71598925Q38749921-F5F4CB55-379C-477D-A113-10EC9320BB9CQ39220049-B5788D06-EA50-416A-AC6E-B1FB1A0E313AQ42586893-31354987-3346-4C15-A6B2-7381400BF472Q43066578-0632D9E9-50D6-46A4-9C10-AB1AA25099F2Q43103936-071F38DC-5D6A-45E9-A308-366E999696D9Q45075694-E8248B1F-B50D-4945-AC34-FA1D0AC513A1Q46145573-360DFE36-FF37-448E-8B70-E1DF09601339Q53366571-40FAF5CF-74E2-49C1-82E2-1710FC68D873Q57518128-C51E1093-D84F-48EF-B67B-157BE9B59115
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Tolcapone: an efficacy and safety review (2007)
@ast
Tolcapone: an efficacy and safety review (2007)
@en
Tolcapone: an efficacy and safety review (2007)
@nl
type
label
Tolcapone: an efficacy and safety review (2007)
@ast
Tolcapone: an efficacy and safety review (2007)
@en
Tolcapone: an efficacy and safety review (2007)
@nl
prefLabel
Tolcapone: an efficacy and safety review (2007)
@ast
Tolcapone: an efficacy and safety review (2007)
@en
Tolcapone: an efficacy and safety review (2007)
@nl
P1476
Tolcapone: an efficacy and safety review (2007)
@en
P2093
Paul B Watkins
P304
P356
10.1097/WNF.0B013E318038D2B6
P407
P577
2007-01-01T00:00:00Z